Janus Henderson Group PLC Eagle Pharmaceuticals, Inc. Transaction History

Janus Henderson Group PLC

$187 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$4.63 - $15.21 $1.69 Million - $5.56 Million	-365,848 Reduced 32.05%	775,525 $4.06 Million
Q3 2023 Nov 14, 2023	SELL	$15.21 - $22.88 $97,313 - $146,386	-6,398 Reduced 0.56%	1,141,373 $18 Million
Q2 2023 Aug 14, 2023	SELL	$17.74 - $31.87 $11,672 - $20,970	-658 Reduced 0.06%	1,147,771 $22.3 Million
Q1 2023 May 15, 2023	SELL	$25.06 - $34.09 $2.04 Million - $2.78 Million	-81,443 Reduced 6.62%	1,148,429 $32.6 Million
Q4 2022 Feb 14, 2023	SELL	$24.98 - $39.77 $247,476 - $394,001	-9,907 Reduced 0.8%	1,229,872 $35.9 Million
Q3 2022 Nov 14, 2022	SELL	$26.42 - $47.12 $5.22 Million - $9.31 Million	-197,535 Reduced 13.74%	1,239,779 $32.8 Million
Q2 2022 Aug 15, 2022	SELL	$41.26 - $51.35 $1.98 Million - $2.47 Million	-48,090 Reduced 3.24%	1,437,314 $63.9 Million
Q1 2022 May 16, 2022	SELL	$44.58 - $52.6 $1.91 Million - $2.25 Million	-42,748 Reduced 2.8%	1,485,404 $73.5 Million
Q4 2021 Feb 14, 2022	BUY	$45.82 - $56.9 $48,111 - $59,745	1,050 Added 0.07%	1,528,152 $77.8 Million
Q3 2021 Nov 16, 2021	SELL	$43.79 - $55.78 $147,791 - $188,257	-3,375 Reduced 0.22%	1,527,102 $85.2 Million
Q2 2021 Aug 16, 2021	SELL	$36.86 - $44.5 $2.22 Million - $2.68 Million	-60,233 Reduced 3.79%	1,530,477 $65.5 Million
Q1 2021 May 17, 2021	SELL	$40.32 - $50.97 $4.17 Million - $5.27 Million	-103,363 Reduced 6.1%	1,590,710 $66.4 Million
Q4 2020 Feb 16, 2021	SELL	$41.72 - $51.34 $194,582 - $239,449	-4,664 Reduced 0.27%	1,694,073 $78.9 Million
Q3 2020 Nov 16, 2020	SELL	$37.02 - $51.28 $292,717 - $405,470	-7,907 Reduced 0.46%	1,698,737 $72.2 Million
Q2 2020 Aug 14, 2020	SELL	$43.24 - $55.02 $2.29 Million - $2.91 Million	-52,850 Reduced 3.0%	1,706,644 $81.9 Million
Q1 2020 May 14, 2020	SELL	$34.37 - $60.07 $1.38 Million - $2.42 Million	-40,215 Reduced 2.23%	1,759,494 $80.9 Million
Q4 2019 Feb 18, 2020	BUY	$54.32 - $64.31 $1.84 Million - $2.18 Million	33,909 Added 1.92%	1,799,709 $108 Million
Q3 2019 Nov 14, 2019	SELL	$53.25 - $59.98 $125,350 - $141,192	-2,354 Reduced 0.13%	1,765,800 $99.9 Million
Q2 2019 Jul 31, 2019	SELL	$46.61 - $58.45 $237,617 - $297,978	-5,098 Reduced 0.29%	1,768,154 $98.5 Million
Q1 2019 Apr 30, 2019	SELL	$38.66 - $51.82 $858,638 - $1.15 Million	-22,210 Reduced 1.24%	1,773,252 $89.5 Million
Q4 2018 Feb 06, 2019	SELL	$36.72 - $67.73 $3.16 Million - $5.83 Million	-86,039 Reduced 4.57%	1,795,462 $72.3 Million
Q3 2018 Nov 09, 2018	SELL	$66.65 - $83.86 $652,970 - $821,576	-9,797 Reduced 0.52%	1,881,501 $130 Million
Q2 2018 Aug 10, 2018	SELL	$51.25 - $76.62 $771,927 - $1.15 Million	-15,062 Reduced 0.79%	1,891,298 $143 Million
Q1 2018 May 14, 2018	BUY	$52.16 - $66.86 $12.8 Million - $16.4 Million	245,479 Added 14.78%	1,906,360 $100 Million
Q4 2017 Feb 09, 2018	SELL	$49.6 - $60.87 $7.26 Million - $8.91 Million	-146,321 Reduced 8.1%	1,660,881 $88.7 Million
Q3 2017 Nov 14, 2017	SELL	$46.62 - $60.36 $1.07 Million - $1.39 Million	-22,997 Reduced 1.26%	1,807,202 $0
Q2 2017 Aug 17, 2017	BUY	N/A	1,830,199	1,830,199 $144 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account